$SPDR S&P Biotech ETF(XBI.US)$$iShares Biotechnology ETF(IBB.US)$ M&A in Q1 alone totaled 12 deals for $19.2 bil which is close to the 10 deals for $21.9 bil in all the 1H of 2023... But one big caveat of this chart, it doesn't include$Pfizer(PFE.US)$'s $43 bil deal for $SGEN announced in Mar 2023 but didn't close until Dec bc of an FTC challenge, The biggest biotech M&A deal so far this yr was$Gilead Sciences(GILD.US)$'s $4.3 b...
$SPDR S&P Biotech ETF(XBI.US)$$iShares Biotechnology ETF(IBB.US)$ Observations from $VINC (-60% AH): 1- When companies tout "strong safety profile", often means efficacy is a big fat zero 2- Phrases like "dose dependent clinical activity" set the bar low 3- "Promising" doesn't necessarily refer to SP Stay skeptical, my friends.
$SPDR S&P Biotech ETF(XBI.US)$$iShares Biotechnology ETF(IBB.US)$ Mike on biotech's correlation with interest rates: "Biotech is essentially a call option on$iShares 20+ Year Treasury Bond ETF(TLT.US)$ Biotech bulls need inflation and rates to move lower for resumption of a real bull market. XBI is likely to remain range-bound - or worse - until inflation convincingly moves lower. Hopefully we can grind out reasonable returns in the meantime by buying the right stocks, but we will b...
Since the beginning of this year,$NVIDIA(NVDA.US)$has been leading a group of semiconductor and AI stocks to further rise in response to the breakthroughs in AI technology and a booming industry outlook. However, an increasing number of investors have started to fret over the potential risks behind the high valuations of AI stocks and are scouting for alternative investment opportunities. Some of them have shifted their focus to biotech stocks...